Vote Scores

Home / Companies / Tango Therapeutics, Inc. / 4 Jun 2026

Meeting · year to 30 June 2026283 filers reporting

Tango Therapeutics, Inc.: meeting of 4 Jun 2026

Votes reported on Form N-PX, item by item

283 Form N-PX filers reported votes at the Tango Therapeutics, Inc. meeting of 4 Jun 2026. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

3 nominees; 56.8% of reported votes for; 58 filers withheld from or voted against at least one nominee.

520 vote records from 91 filers. 32 of the 90 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

62.6% for0.0% against37.4% other35.6% against management91 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

418 vote records from 281 filers. 21 of the 268 filers that marked the item either way voted against management. 13 filers reported this item without a management mark.

87.9% for6.8% against5.3% other7.8% against management281 filers98.7% for1.3% against0.0% other1.3% against management119,906,112 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

173 vote records from 90 filers. 0 of the 89 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

98.9% for0.0% against1.1% other0.0% against management90 filers100.0% for0.0% against0.0% against management16,037,002 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesForForFor
FidelityForForFor
DimensionalAbstain or withhold *ForFor
State Street and SPDRForForFor
Franklin TempletonForForFor
InvescoForAgainst *For
EquitableForForFor
Charles SchwabForForFor
Nuveen and TIAAAbstain or withhold *ForFor
ProShares and ProFundsAbstain or withhold *ForFor
John Hancock and ManulifeForForFor
Morgan Stanley, Eaton Vance and CalvertAbstain or withhold *ForFor
J.P. MorganNo reportForNo report
Goldman SachsForForFor
PGIM and PrudentialNo reportForNo report
Jackson National fundsForForFor
Northern Trust and FlexSharesForForFor
SEIForForFor
T. Rowe PriceForForFor
Lincoln FinancialForForFor
VoyaAbstain or withhold *ForFor
First TrustNo reportAgainst *No report
Russell InvestmentsNo reportForNo report
NationwideForForFor
Victory CapitalAbstain or withhold *ForFor
Brighthouse FundsAbstain or withholdForFor
Guggenheim and RydexAbstain or withhold *ForFor
Columbia ThreadneedleForForFor
BNY MellonNo reportForNo report
PrincipalAbstain or withhold *ForFor
Pacific Life fundsForForFor
Global XForForFor
MFSAbstain or withhold *ForFor
Federated HermesNo reportForNo report
AllianceBernsteinNo reportForNo report
DWSAbstain or withhold *ForFor
AllspringNo reportSplit or no voteNo report
MassMutualNo reportForNo report
Janus HendersonNo reportForNo report
Neuberger BermanNo reportForNo report
Natixis and Loomis SaylesNo reportForNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Tango Therapeutics, Inc. meeting?

283 Form N-PX filers reported votes at the meeting of 4 Jun 2026. On say-on-pay, 21 of 268 voted against management (7.8%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Tango Therapeutics, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Tango Therapeutics, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Tango Therapeutics, Inc. with a meeting date within three days of 4 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.